Cell therapy (CAR-T) · Kills target cells, directed at guanylyl cyclase C (GUCY2C)
LCAR-G08 is an autologous T-lymphocyte preparation genetically engineered with a lentiviral vector to express a chimeric antigen receptor targeting guanylyl cyclase C (GUCY2C), an enterocyte differentiation antigen overexpressed on various tumor cells. The engineered cells are directed to GCC-expressing tumor cells, where they activate, proliferate and release cytokines to kill them. It is being studied in advanced gastrointestinal tumors.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06197178 | Phase 1 | Advanced Gastrointestinal Tumors | Terminated | LEGN |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Advanced Gastrointestinal Tumors